The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,671.50
Bid: 1,671.00
Ask: 1,671.50
Change: 1.50 (0.09%)
Spread: 0.50 (0.03%)
Open: 1,661.50
High: 1,679.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares, ADSs

Tue, 15th Apr 2014 15:08

LONDON (Alliance News) - GlaxoSmithKline PLC Tuesday said a group of executives, including Chief Executive Andrew Witty, acquired shares and American Depositary Shares under the 2009 deferred annual bonus plan at a price of 1581.50 pence per share and USD53.42 per ADS each following a dividend reinvestment.

Details are as follows.

Sir Andrew Witty

Acquisition of 2,101 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 2,101 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr S Dingemans

Acquisition of 924 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 924 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Dr M M Slaoui

Acquisition of 791 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 791 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr S M Bicknell

Acquisition of 210 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 210 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mrs D P Connelly

Acquisition of 153 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 153 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr R G Connor

Acquisition of 236 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 236 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr S A Hussain

Acquisition of 119 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 119 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr W C Louv

 

Acquisition of 191 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 191 ADSs under the matching element of the Plan (Company contribution).

 

 

Mr D S Redfern

Acquisition of 449 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 449 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Ms C Thomas 

Acquisition of 338 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 338 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr P C Thomson

Acquisition of 69 Ordinary Shares under the personal contribution element of the Plan.

 

 

 

Acquisition of 69 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Mr D E Troy

Acquisition of 350 ADSs under the personal contribution element of the Plan.

 

 

 

Acquisition of 350 ADSs under the matching element of the Plan (Company contribution).

 

 

Dr P J T Vallance

Acquisition of 986 Ordinary Shares under the personal contribution element of the Plan.

 

 

Acquisition of 986 Ordinary Shares under the matching element of the Plan (Company contribution).

 

 

Ms E Walmsley

Acquisition of 544 Ordinary Shares under the personal contribution element of the Plan.

 

 

Acquisition of 544 Ordinary Shares under the matching element of the Plan (Company contribution).

 



Shares in the global healthcare company were trading at 1,549.00 pence up 0.4% Tuesday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright © 2014 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.